发布求助
文献互助 智能选刊 最新文献

Current Opinion in Pharmacology最新文献

筛选
英文 中文
Message from the New Editor-in-Chief, Prof. Sheng-Tao Hou
IF 4 3区 医学
Current Opinion in Pharmacology Pub Date : 2025-02-01 DOI: 10.1016/j.coph.2024.102504
Sheng-Tao Hou
{"title":"Message from the New Editor-in-Chief, Prof. Sheng-Tao Hou","authors":"Sheng-Tao Hou","doi":"10.1016/j.coph.2024.102504","DOIUrl":"10.1016/j.coph.2024.102504","url":null,"abstract":"","PeriodicalId":50603,"journal":{"name":"Current Opinion in Pharmacology","volume":"80 ","pages":"Article 102504"},"PeriodicalIF":4.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143025552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
In memoriam - Francesco di Virgilio: P2X7 receptors in purinergic pathophysiology
IF 4 3区 医学
Current Opinion in Pharmacology Pub Date : 2025-02-01 DOI: 10.1016/j.coph.2024.102503
P. Illes , A. Verkhratsky , Y. Tang , P. Rubini , E. Adinolfi
{"title":"In memoriam - Francesco di Virgilio: P2X7 receptors in purinergic pathophysiology","authors":"P. Illes , A. Verkhratsky , Y. Tang , P. Rubini , E. Adinolfi","doi":"10.1016/j.coph.2024.102503","DOIUrl":"10.1016/j.coph.2024.102503","url":null,"abstract":"","PeriodicalId":50603,"journal":{"name":"Current Opinion in Pharmacology","volume":"80 ","pages":"Article 102503"},"PeriodicalIF":4.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143043271","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Regulation of pathway choice in DNA repair after double-strand breaks 双链断裂后DNA修复的途径选择调控。
IF 4 3区 医学
Current Opinion in Pharmacology Pub Date : 2025-02-01 DOI: 10.1016/j.coph.2024.102496
Nitu Kumari , Ekjot Kaur , Sathees C. Raghavan , Sagar Sengupta
{"title":"Regulation of pathway choice in DNA repair after double-strand breaks","authors":"Nitu Kumari ,&nbsp;Ekjot Kaur ,&nbsp;Sathees C. Raghavan ,&nbsp;Sagar Sengupta","doi":"10.1016/j.coph.2024.102496","DOIUrl":"10.1016/j.coph.2024.102496","url":null,"abstract":"<div><div>DNA damage signaling is a highly coordinated cellular process which is required for the removal of DNA lesions. Amongst the different types of DNA damage, double-strand breaks (DSBs) are the most harmful type of lesion that attenuates cellular proliferation. DSBs are repaired by two major pathways—homologous recombination (HR), and non-homologous end-joining (NHEJ) and in some cases by microhomology-mediated end-joining (MMEJ). Preference of the pathway depends on multiple parameters including site of the DNA damage, the cell cycle phase and topology of the DNA lesion. Deregulated repair response contributes to genomic instability resulting in a plethora of diseases including cancer. This review discusses the different molecular players of HR, NHEJ, and MMEJ pathways that control the switch among the different DSB repair pathways. We also highlight the various functions of chromatin modifications in modulating repair response and how deregulated DNA damage repair response may promote oncogenic transformation.</div></div>","PeriodicalId":50603,"journal":{"name":"Current Opinion in Pharmacology","volume":"80 ","pages":"Article 102496"},"PeriodicalIF":4.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142900094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Oncohistone-sculpted epigenetic mechanisms in pediatric brain cancer
IF 4 3区 医学
Current Opinion in Pharmacology Pub Date : 2025-01-09 DOI: 10.1016/j.coph.2025.102505
Deo Prakash Pandey , Kumar Somyajit
{"title":"Oncohistone-sculpted epigenetic mechanisms in pediatric brain cancer","authors":"Deo Prakash Pandey ,&nbsp;Kumar Somyajit","doi":"10.1016/j.coph.2025.102505","DOIUrl":"10.1016/j.coph.2025.102505","url":null,"abstract":"<div><div>Chromatin dynamics, involving reversible changes in chromatin structure, shape key cellular processes and genomic integrity during development and proliferation, with disruptions leading to cancer. Histones, core components of chromatin and substrates for chromatin-modifying enzymes, play crucial roles in oncogenesis when misregulated or mutated. This is particularly pronounced in pediatric hind brain cancers, some of which are driven primarily by the oncohistone H3K27M and the recently identified oncohistone-mimic protein CXorf67/EZHIP. Notably, H3K27M and EZHIP-driven cancers exhibit low mutation burdens, highlighting the enigmatic role of non-mutational epigenetic reprogramming in oncogenesis beyond traditional paradigms of oncogene activation and tumor suppressor loss. Here, we review the impact of H3K27M and EZHIP-driven cancer mechanisms on chromatin and transcriptional dysregulation leading to aberrant cell fate determination, and their potential influence beyond gene activity, affecting broader cellular pathways. Illuminating these mechanisms is crucial for advancing treatment options for pediatric brain cancers, where therapeutic regimens are poorly defined.</div></div>","PeriodicalId":50603,"journal":{"name":"Current Opinion in Pharmacology","volume":"81 ","pages":"Article 102505"},"PeriodicalIF":4.0,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143061417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Could positive allosteric modulators of the cannabinoid CB1 receptor be efficacious and safe for the treatment of chronic pain? 大麻素 CB1 受体的正性异位调节剂能否安全有效地治疗慢性疼痛？
IF 4 3区 医学
Current Opinion in Pharmacology Pub Date : 2024-10-23 DOI: 10.1016/j.coph.2024.102495
Hayley M. Green , Michelle Glass
{"title":"Could positive allosteric modulators of the cannabinoid CB1 receptor be efficacious and safe for the treatment of chronic pain?","authors":"Hayley M. Green ,&nbsp;Michelle Glass","doi":"10.1016/j.coph.2024.102495","DOIUrl":"10.1016/j.coph.2024.102495","url":null,"abstract":"<div><div>Cannabinoids are effective analgesics but induce adverse cannabimimetic effects and the development of tolerance. Allosteric ligands of the cannabinoid CB<sub>1</sub> receptor (CB<sub>1</sub>) may harness the pain-relieving effects of cannabinoids with reduced adverse effects. CB<sub>1</sub> allosteric ligands bind at a site topographically distinct from the orthosteric binding site. CB<sub>1</sub> allosteric ligands have been shown to be effective pain-relieving drugs that do not appear to result in the production of adverse effects or the development of tolerance. While this therapeutic profile indicates that CB<sub>1</sub> allosteric ligands could be an effective treatment for chronic pain, their molecular mechanism of action remains unclear.</div></div>","PeriodicalId":50603,"journal":{"name":"Current Opinion in Pharmacology","volume":"79 ","pages":"Article 102495"},"PeriodicalIF":4.0,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142644910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Role of specific CDKs in regulating DNA damage repair responses and replication stress 特定 CDK 在调节 DNA 损伤修复反应和复制压力中的作用
IF 4 3区 医学
Current Opinion in Pharmacology Pub Date : 2024-09-10 DOI: 10.1016/j.coph.2024.102485
Rahul Roy , Siri Chandana Gampa , Sireesha V. Garimella
{"title":"Role of specific CDKs in regulating DNA damage repair responses and replication stress","authors":"Rahul Roy ,&nbsp;Siri Chandana Gampa ,&nbsp;Sireesha V. Garimella","doi":"10.1016/j.coph.2024.102485","DOIUrl":"10.1016/j.coph.2024.102485","url":null,"abstract":"<div><p>Cyclins along with their catalytic units, Cyclin-dependent kinases (CDKs) regulate the cell cycle transition and transcription; and are essentially known as ‘master regulators’ in modulating DNA damage response (DDR) and replication stress. In addition to influencing DNA repair and damage signaling, CDKs also play a pivotal role in cell division fidelity and the maintenance of genomic integrity after DNA damage. In this review, we focus on the intricate ways by which specific CDKs mainly CDK7, CDK9, and CDK12/13, regulate the cell cycle progression and transcription and how their modulation can lead to lethal effects on the integrity of the genome. With a better knowledge of how these CDKs control the DDR and replication stress, it is now possible to combine CDK inhibitors with chemotherapeutic drugs that damage DNA in ways that can be applied in clinical settings as successful therapeutic strategies.</p></div>","PeriodicalId":50603,"journal":{"name":"Current Opinion in Pharmacology","volume":"79 ","pages":"Article 102485"},"PeriodicalIF":4.0,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142168456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Therapeutic innovations for geographic atrophy: A promising horizon 地理萎缩的治疗创新：前景光明。
IF 4 3区 医学
Current Opinion in Pharmacology Pub Date : 2024-09-06 DOI: 10.1016/j.coph.2024.102484
Eva C. de Oliveira Figueiredo , Claudio Bucolo , Chiara M. Eandi
{"title":"Therapeutic innovations for geographic atrophy: A promising horizon","authors":"Eva C. de Oliveira Figueiredo ,&nbsp;Claudio Bucolo ,&nbsp;Chiara M. Eandi","doi":"10.1016/j.coph.2024.102484","DOIUrl":"10.1016/j.coph.2024.102484","url":null,"abstract":"<div><p>This mini review spotlights the most promising treatments for geographic atrophy, the advanced form of age-related macular degeneration, often resulting in severe and irreversible vision loss. The pathophysiology is complex, and various therapeutic strategies, including anticomplement therapies, gene therapies, cell-based interventions, and artificial intelligence–driven diagnostics are discussed.</p><p>Anticomplement therapies (antifactors C3 and C5) showed promise in reducing the inflammatory response and the progression of the atrophy. Gene therapies, targeting specific genetic mutations, are under development to correct underlying defects and potentially reverse disease progression. Cell-based therapies are gaining momentum, with early studies indicating encouraging results in the replacement of damaged retinal pigment epithelium cells.</p></div>","PeriodicalId":50603,"journal":{"name":"Current Opinion in Pharmacology","volume":"78 ","pages":"Article 102484"},"PeriodicalIF":4.0,"publicationDate":"2024-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1471489224000547/pdfft?md5=df5b4fff4283445369fb45638e495d89&pid=1-s2.0-S1471489224000547-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142146764","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Targeting the soluble epoxide hydrolase pathway as a novel therapeutic approach for the treatment of pain 将可溶性环氧化物水解酶途径作为治疗疼痛的一种新方法
IF 4 3区 医学
Current Opinion in Pharmacology Pub Date : 2024-08-27 DOI: 10.1016/j.coph.2024.102477
James Turnbull, Victoria Chapman
{"title":"Targeting the soluble epoxide hydrolase pathway as a novel therapeutic approach for the treatment of pain","authors":"James Turnbull,&nbsp;Victoria Chapman","doi":"10.1016/j.coph.2024.102477","DOIUrl":"10.1016/j.coph.2024.102477","url":null,"abstract":"<div><p>Chronic pain is a major burden and the complexities of chronic pain pathophysiology, including both peripheral and central sensitisation mechanisms, involves multiple cell types (neuronal, immune, neuroimmune, and vascular) which substantially complicates the development of new effective analgesic treatments. The epoxy fatty acids (EpFAs), including the epoxyeicosatrienoic acids (EETs), are derived from the metabolism of polyunsaturated fatty acids (PUFAs) via the cytochrome P450 enzymatic pathway and act to shut-down inflammatory signalling and provide analgesia. The EpFAs are rapidly metabolised by the enzyme soluble epoxide hydrolase (sEH) into their corresponding diol metabolites, which recent studies suggest are pro-inflammatory and pro-nociceptive. This review discusses clinical and mechanistic evidence for targeting the sEH pathway for the treatment of pain.</p></div>","PeriodicalId":50603,"journal":{"name":"Current Opinion in Pharmacology","volume":"78 ","pages":"Article 102477"},"PeriodicalIF":4.0,"publicationDate":"2024-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S147148922400047X/pdfft?md5=a9b581da49f5aa67863f4733f9fed885&pid=1-s2.0-S147148922400047X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142084204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Native botulinum toxin type A vs. redesigned botulinum toxins in pain: What did we learn so far? A型肉毒杆菌毒素与重新设计的肉毒杆菌毒素在疼痛治疗中的对比：迄今为止我们学到了什么？
IF 4 3区 医学
Current Opinion in Pharmacology Pub Date : 2024-08-22 DOI: 10.1016/j.coph.2024.102476
Ivica Matak, Zdravko Lacković
{"title":"Native botulinum toxin type A vs. redesigned botulinum toxins in pain: What did we learn so far?","authors":"Ivica Matak,&nbsp;Zdravko Lacković","doi":"10.1016/j.coph.2024.102476","DOIUrl":"10.1016/j.coph.2024.102476","url":null,"abstract":"<div><p>Driven by the clinical success of botulinum toxin serotype A (BoNT/A) and the need for improved chronic pain management, researchers attempted to develop re-designed botulinum toxin (BoNT)-based molecules as novel analgesics. Various recombinant protein expression strategies including retargeted binding domains, and chimeric toxins combining different serotypes were tested to improve BoNT/A therapeutic safety margin and expand its efficacy. The aim of this review is to re-evaluate the current design strategies for recombinant BoNT-based molecules for pain treatment, compares their analgesic profile against the native BoNT/A, as well as to discuss the main strengths and potential weaknesses of reported approaches.</p></div>","PeriodicalId":50603,"journal":{"name":"Current Opinion in Pharmacology","volume":"78 ","pages":"Article 102476"},"PeriodicalIF":4.0,"publicationDate":"2024-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142044637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Preoperative optimization: Review on nutritional assessment and strategies in IBD 术前优化：回顾 IBD 的营养评估和策略。
IF 4 3区 医学
Current Opinion in Pharmacology Pub Date : 2024-08-01 DOI: 10.1016/j.coph.2024.102475
Julie Vanderstappen , Sien Hoekx , Gabriele Bislenghi , André D'Hoore , Bram Verstockt , João Sabino
{"title":"Preoperative optimization: Review on nutritional assessment and strategies in IBD","authors":"Julie Vanderstappen ,&nbsp;Sien Hoekx ,&nbsp;Gabriele Bislenghi ,&nbsp;André D'Hoore ,&nbsp;Bram Verstockt ,&nbsp;João Sabino","doi":"10.1016/j.coph.2024.102475","DOIUrl":"10.1016/j.coph.2024.102475","url":null,"abstract":"<div><p>Inflammatory bowel diseases (IBD), encompassing conditions like Crohn's disease and ulcerative colitis, present multifaceted challenges requiring a comprehensive management approach. Patients often necessitate a combination of medical therapy, surgical interventions, and nutritional support. Despite advancements in medical and dietary therapies, the prevalence of surgery remains high among the IBD population, alongside the persistent risk of malnutrition. Preoperative nutritional optimization has thus become a critical element in the perioperative pathway, given its association with improved surgical outcomes. However, standardized protocols for preoperative optimization of IBD patients are lacking, and available data are mainly retrospective.</p><p>This review provides an overview of the current knowledge on preoperative nutritional screening and optimization in IBD patients and identifies avenues for future research and clinical practice.</p><p>Interdisciplinary collaboration among healthcare professionals, including gastroenterologists, surgeons, dietitians, physiotherapists, and psychologists, is crucial for comprehensive preoperative nutritional management in IBD patients. By addressing the interplay between inflammation, malnutrition, and surgical risk, clinicians can strive to enhance surgical care and postoperative outcomes.</p><p>In conclusion, while recognizing the importance of preoperative nutritional optimization in improving surgical outcomes for IBD patients, challenges persist in standardizing management protocols. Prospective studies are needed to establish such protocols and evaluate the effectiveness of different nutritional strategies.</p></div>","PeriodicalId":50603,"journal":{"name":"Current Opinion in Pharmacology","volume":"77 ","pages":"Article 102475"},"PeriodicalIF":4.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141914448","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信